| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Gary W Pace is Director at CRDF, with reported holdings spanning 3 companies. From March 2015 to July 2026, the filings on record show 16 open-market purchases and 4 sales. Gary W Pace's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $25.4M at current prices.
Our model assigns Gary W Pace a middling insider score of 66/100, based on 16 past trades. Over a 12-month horizon, 69.2% of those trades were profitable, with an average 12-month return of +9.0%.
Gary W Pace's largest disclosed position is in RMD as Director, worth about $22.8M. The RMD filings lean toward selling, a net 28,403 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 21, 2021 | CRDF Cardiff Oncology, Inc. | Director | Buy | 30,000 | $6.75 | $202,500.00 | +6.5% | -8.8% | -74.3% | |
| Mar 23, 2021 | CRDF Cardiff Oncology, Inc. | Director | Buy | 10,000 | $10.23 | $102,300.00 | +2.2% | -22.3% | -75.7% | |
| Mar 18, 2021 | CRDF Cardiff Oncology, Inc. | Director | Buy | 3,000 | $10.55 | $31,660.00 | +0.7% | -22.6% | -75.1% | |
| Mar 4, 2021 | CRDF Cardiff Oncology, Inc. | Director | Buy | 1,500 | $9.27 | $13,897.50 | +0.3% | - | - | |
| Sep 16, 2020 | CRDF Cardiff Oncology, Inc. | Director | Buy | 2,550 | $5.70 | $14,526.50 | +0.6% | - | - | |
| May 11, 2020 | CRDF Cardiff Oncology, Inc. | Director | Buy | 447,761 | $1.34 | $599,999.74 | New | - | - | |
| Nov 19, 2018 | PCRX Pacira Biosciences, Inc. | Director | Buy | 4,500 | $46.18 | $207,810.00 | +15.9% | - | - | |
| Nov 7, 2018 | PCRX Pacira Biosciences, Inc. | Director | Buy | 4,000 | $51.29 | $205,160.00 | +16.4% | - | - | |
| May 8, 2018 | RMD Resmed Inc | Director | Sale+OE | 28,403 | $97.37 | $2,765,600.11 | -22.0% | - | - | |
| Mar 13, 2015 | PCRX Pacira Biosciences, Inc. | Director | Buy | 1,000 | $93.83 | $93,829.90 | +5.7% | - | - |